Proviral sequencing driven development of enhanced IPDAV2 with global HIV-1 group m coverage to support worldwide cure and clinical trials
Ended Definitive Contract Awarded Last action
- Contract number
- 75N93023C00017
- Awardee
-
Accelevir Diagnostics LLC UEI F6SKM7YHCUS7
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,000,000
Award facts
- Opportunity
-
- SBIRPHS20201 Solicitation number
- Contract value 100% obligated
- $2,000,000.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 1 offer Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Baltimore, MD 21202, USA
- Research
- SBIR Program Phase II Action
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $2,000,000 |
About this award
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $2M definitive contract to Accelevir Diagnostics LLC of East Case, MD. The contract is for ProViral Sequencing Driven Development of EnHanced IPDAV2 with Global HIV-1 Group M Coverage to Support Worldwide Cure and Clinical Trials. The prime contractor will perform research and development of enhanced diagnostics to support global HIV cure and clinical trials under this Small Business Innovation Research Program Phase II Action contract. The period of performance is from June 1, 2023 through May 31, 2025 under firm fixed pricing. The contract was set aside for total small businesses.
Quick answers
Who was awarded contract 75N93023C00017?
75N93023C00017 was awarded to Accelevir Diagnostics LLC by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on June 1, 2023.
How much is contract 75N93023C00017 worth?
The government has obligated $2,000,000 on 75N93023C00017.
Was contract 75N93023C00017 competed?
The extent of competition for 75N93023C00017 was full and open competition after exclusion of sources. The government received 1 offer. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award